BR112022014849A2 - Métodos de tratamento de um tumor sólido, métodos para induzir a proliferação de células t, para induzir a proliferação de células nk e para induzir a produção de ifny - Google Patents
Métodos de tratamento de um tumor sólido, métodos para induzir a proliferação de células t, para induzir a proliferação de células nk e para induzir a produção de ifnyInfo
- Publication number
- BR112022014849A2 BR112022014849A2 BR112022014849A BR112022014849A BR112022014849A2 BR 112022014849 A2 BR112022014849 A2 BR 112022014849A2 BR 112022014849 A BR112022014849 A BR 112022014849A BR 112022014849 A BR112022014849 A BR 112022014849A BR 112022014849 A2 BR112022014849 A2 BR 112022014849A2
- Authority
- BR
- Brazil
- Prior art keywords
- induce
- methods
- cell proliferation
- treatment
- solid tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Abstract
MÉTODOS DE TRATAMENTO DE UM TUMOR SÓLIDO, MÉTODOS PARA INDUZIR A PROLIFERAÇÃO DE CÉLULAS T, PARA INDUZIR A PROLIFERAÇÃO DE CÉLULAS NK E PARA INDUZIR A PRODUÇÃO DE IFN?. A presente divulgação fornece métodos de tratamento de câncer por meio da administração de uma proteína heterodimérica que compreende um primeiro monômero que compreende uma fusão de proteína IL15-domínio Fc e um segundo monômero que compreende uma fusão de proteína IL15Ra-domínio Fc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966976P | 2020-01-28 | 2020-01-28 | |
PCT/US2021/015552 WO2021155042A1 (en) | 2020-01-28 | 2021-01-28 | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022014849A2 true BR112022014849A2 (pt) | 2022-10-11 |
Family
ID=74672461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022014849A BR112022014849A2 (pt) | 2020-01-28 | 2021-01-28 | Métodos de tratamento de um tumor sólido, métodos para induzir a proliferação de células t, para induzir a proliferação de células nk e para induzir a produção de ifny |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230149509A1 (pt) |
EP (1) | EP4096698A1 (pt) |
JP (1) | JP2023511439A (pt) |
KR (1) | KR20220132598A (pt) |
CN (1) | CN115397456A (pt) |
AU (1) | AU2021213767A1 (pt) |
BR (1) | BR112022014849A2 (pt) |
CA (1) | CA3165460A1 (pt) |
IL (1) | IL294944A (pt) |
MX (1) | MX2022009100A (pt) |
TW (1) | TW202136318A (pt) |
WO (1) | WO2021155042A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
CA3225405A1 (en) * | 2021-07-28 | 2023-02-02 | Alexander Joachim Paul Ungewickell | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
WO2023015198A1 (en) * | 2021-08-04 | 2023-02-09 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours |
WO2024011179A1 (en) | 2022-07-07 | 2024-01-11 | Genentech, Inc. | Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and fcrh5xcd3 bispecific antibodies for the treatment of blood cancers |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
ES2027518A6 (es) | 1990-12-18 | 1992-06-01 | Andromaco Lab | Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica. |
US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
US6071535A (en) | 1996-01-31 | 2000-06-06 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
US5874105A (en) | 1996-01-31 | 1999-02-23 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
WO1998048032A2 (en) | 1997-04-21 | 1998-10-29 | Donlar Corporation | POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US7195780B2 (en) | 2002-10-21 | 2007-03-27 | University Of Florida | Nanoparticle delivery system |
US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
EP1474108A2 (en) | 2002-01-09 | 2004-11-10 | Enzrel, Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
DE60314495T2 (de) | 2002-02-07 | 2008-03-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Aminosäuresequenzen, die in der lage sind die durchdringung einer biologischen barriere zu erleichtern |
AU2003248370A1 (en) | 2002-02-27 | 2003-09-09 | California Institute Of Technology | Computational method for designing enzymes for incorporation of amino acid analogs into proteins |
US7090868B2 (en) | 2002-09-13 | 2006-08-15 | University Of Florida | Materials and methods for drug delivery and uptake |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
JP2007523050A (ja) | 2003-09-17 | 2007-08-16 | カイアズマ・リミテッド | 生物学的障壁を通した透過を容易にすることのできる組成物 |
SG143252A1 (en) | 2003-10-09 | 2008-06-27 | Ambrx Inc | Polymer derivatives |
AU2005211362B2 (en) | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
WO2006097793A2 (en) | 2004-04-15 | 2006-09-21 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
WO2006062506A1 (en) | 2004-12-03 | 2006-06-15 | Enzrel, Inc. | Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
US20070184076A1 (en) | 2006-02-07 | 2007-08-09 | Unger Evan C | Liquid-filled nanodroplets for anti-cancer therapy |
IL188647A0 (en) | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
KR101001360B1 (ko) | 2008-06-16 | 2010-12-14 | (주)기가레인 | 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판 |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Pd−l1/pd−l2の同時阻害 |
LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
AU2014225822B2 (en) | 2013-03-05 | 2017-05-04 | Enteris Biopharma, Inc. | Pharmaceuticals for oral delivery |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
ES2929218T3 (es) | 2015-01-12 | 2022-11-28 | Enteris Biopharma Inc | Formas farmacéuticas orales sólidas |
AU2017342559B2 (en) | 2016-10-14 | 2022-03-24 | Xencor, Inc. | Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments |
IL278090B1 (en) * | 2018-04-18 | 2024-03-01 | Xencor Inc | Proteins from heterodimeric il-15/il-15rα ohi-fc and their uses |
-
2021
- 2021-01-28 CA CA3165460A patent/CA3165460A1/en active Pending
- 2021-01-28 CN CN202180010911.0A patent/CN115397456A/zh active Pending
- 2021-01-28 BR BR112022014849A patent/BR112022014849A2/pt unknown
- 2021-01-28 TW TW110103329A patent/TW202136318A/zh unknown
- 2021-01-28 WO PCT/US2021/015552 patent/WO2021155042A1/en unknown
- 2021-01-28 JP JP2022544745A patent/JP2023511439A/ja active Pending
- 2021-01-28 MX MX2022009100A patent/MX2022009100A/es unknown
- 2021-01-28 EP EP21707111.7A patent/EP4096698A1/en active Pending
- 2021-01-28 KR KR1020227029305A patent/KR20220132598A/ko unknown
- 2021-01-28 AU AU2021213767A patent/AU2021213767A1/en active Pending
- 2021-01-28 IL IL294944A patent/IL294944A/en unknown
-
2022
- 2022-07-22 US US17/814,456 patent/US20230149509A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4096698A1 (en) | 2022-12-07 |
KR20220132598A (ko) | 2022-09-30 |
JP2023511439A (ja) | 2023-03-17 |
CA3165460A1 (en) | 2021-08-05 |
AU2021213767A1 (en) | 2022-07-28 |
TW202136318A (zh) | 2021-10-01 |
MX2022009100A (es) | 2022-08-18 |
WO2021155042A1 (en) | 2021-08-05 |
CN115397456A (zh) | 2022-11-25 |
IL294944A (en) | 2022-09-01 |
US20230149509A1 (en) | 2023-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022014849A2 (pt) | Métodos de tratamento de um tumor sólido, métodos para induzir a proliferação de células t, para induzir a proliferação de células nk e para induzir a produção de ifny | |
BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
BR112017020445A2 (pt) | polipeptídeo de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de um polipeptídeo de fusão, uso do polipeptídeo de fusão, método para ativar as vias de sinalização, método para coestimular células, método para induzir a proliferação de linfócitos e método para direcionar o agrupamento de cd137 | |
BR112018000366A2 (pt) | polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão | |
BR112019007281A2 (pt) | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente | |
BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
PH12020552039A1 (en) | Binding molecules against bcma and uses thereof | |
BR112017020434A2 (pt) | polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2 | |
EP4249064A3 (en) | Novel fusion protein specific for cd137 and pd-l1 | |
BR112018007538A2 (pt) | células exterminadoras naturais e células ilc3 e usos das mesmas | |
BR112021010354A2 (pt) | Métodos para o tratamento usando terapia celular adotiva | |
MX2019010382A (es) | Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva. | |
BR112022001148A2 (pt) | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto | |
PH12019500643A1 (en) | Antibodies that bind interleukin-2 and uses thereof | |
PH12015501796A1 (en) | Il-1b inhibitor composition and use thereof | |
CO2022015202A2 (es) | Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos | |
WO2019173902A8 (en) | Combination of cd47 blockade therapy and a cd38 antibody | |
BR112017024431A2 (pt) | método de tratamento de um ebv-lpd | |
BR112022024404A2 (pt) | Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus | |
AR095387A1 (es) | Proteínas específicas para el baff y para la b7rp1 y sus usos | |
MX2021002500A (es) | Anticuerpos y secuencias de nucleotidos novedosos, y sus usos. | |
BR112023018832A2 (pt) | Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas | |
BR112023002668A2 (pt) | Composições e métodos para tratar cânceres egfr positivos | |
BR112022014501A2 (pt) | Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva | |
CR20220244A (es) | Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas |